Gilead Sciences, Inc., 10% Owner at Kyverna Therapeutics, Inc. (KYTX), bought 4,126,119 shares at $22.00 ($20.0M) on 2024-02-12, disclosed to the SEC on 2024-02-13.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 3,216,119 | $0 | 0.0% |
| 2 | $22.00 | 910,000 | $20.0M | 100.0% |
| Total | $4.85 avg | 4,126,119 | $20.0M | 100% |
| Filing → |
| XLO | BUY | 2024-12-19 | $3.7M | — | Filing → |
| XLO | BUY | 2024-04-03 | $369K | — | Filing → |
| RCUS | BUY | 2024-01-31 | $320.0M | — | Filing → |